Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Angiographic Trials of Lipid‐Lowering Therapy

Angiographic Trials of Lipid‐Lowering Therapy Human trials of lipid-lowering therapy for atherosclerosis have conventionally measured the rate at which symptoms of coronary heart disease become clinically manifest. These trials require observation of a large number of subjects for several years. An alternative strategy is to measure progression or regression of atherosclerosis, using the rate of change in lesions as an endpoint. Computer processing of angiograms has been developed to estimate atherosclerotic lesion change rates in the femoral artery. This paper presents estimates of patient-to-patient variability and measurement error in computer-processed femoral angiograms using data from 79 subjects. The feasibility of small, relatively short-term trials of lipid-lowering therapy on femoral atherosclerosis is demonstrated. Also projected are the cost, length, and power of trials with 120 subjects in test and control groups. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis Wolters Kluwer Health

Angiographic Trials of Lipid‐Lowering Therapy

Arteriosclerosis , Volume 1 (4) – Jul 1, 1981

Loading next page...
 
/lp/wolters-kluwer-health/angiographic-trials-of-lipid-hyphen-lowering-therapy-o7n7UUvY1v
Copyright
© 1981 by American Heart Association, Inc.
ISSN
0276-5047

Abstract

Human trials of lipid-lowering therapy for atherosclerosis have conventionally measured the rate at which symptoms of coronary heart disease become clinically manifest. These trials require observation of a large number of subjects for several years. An alternative strategy is to measure progression or regression of atherosclerosis, using the rate of change in lesions as an endpoint. Computer processing of angiograms has been developed to estimate atherosclerotic lesion change rates in the femoral artery. This paper presents estimates of patient-to-patient variability and measurement error in computer-processed femoral angiograms using data from 79 subjects. The feasibility of small, relatively short-term trials of lipid-lowering therapy on femoral atherosclerosis is demonstrated. Also projected are the cost, length, and power of trials with 120 subjects in test and control groups.

Journal

ArteriosclerosisWolters Kluwer Health

Published: Jul 1, 1981

There are no references for this article.